Bingham McCutchen: Foreign Establishment in US Markets




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Bingham McCutchen: Foreign Establishment in US Markets
Released on: June 01, 2007. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Fintan Walton talks to Brian Beglin, a partner at Bingham McCutchen.
  • Summary
  • Participants
  • Company
Fintan Walton talks to Brian Beglin, a partner at Bingham McCutchen. The interview begins with a discussion of the strengths of the markets at this present time, of the surge in M&A activity combined with the reduction in company IPOs, and of the appeal for foreign companies to be listed in US markets. It moves on to look at the very active area of PIPES (private investment in public equities), and why this option may be more attractive to non-US companies who are prepared to issue shares to US investors. The increase in available capital to companies with products that are at least in Phase II-Phase IIb development is covered, followed by a more detailed examination of M&A deals, and how these can transition from what may initially have been partnering talks. The issues associated with non-US companies making acquisitions in the US are considered, followed by the strategies that these companies might employ to acquire co-promotion rights in the US. The interview concludes with Brian's prediction for which types of deals will be the primary focus for biotech companies in the coming year.
Brian Beglin is Co-Chair of Bingham's Life Sciences Industry Group. His practice includes general business and corporate law with an emphasis on mergers and acquisitions, corporate finance, licensing and joint ventures. Brian's mergers and acquisitions experience covers a broad range of industries, including biopharmaceuticals, basic manufacturing, technology, food products and transportation. As regards corporate finance, Brian's practice ranges from public offerings and private placements of debt and equity securities, to going-private transactions, licensing and joint ventures, to cross-border PIPES. His experience also includes structuring minority investments in business enterprises, where he has represented both issuers and investors.
Bingham McCutchen